Sign up USA
Proactive Investors - Run By Investors For Investors

Aldeyra Therapeutics reports positive results from a phase 2a trial of its treatment for dry eye disease

In a statement, the Nasdaq-listed company said that based on statistically and clinically significant activity across a number of sign and symptom endpoints and tolerability, the ADX-102 treatment was nominated for advancement
Dry eye treatment
The group said it now expects to initiate a phase 2b trial in the first half of 2018

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) saw its shares soar over 50% higher in premarket trade after the biotechnology company reported positive results from a phase 2a trial of its treatment for dry eye disease.

In a statement, the Nasdaq-listed company said that based on statistically and clinically significant activity across a number of sign and symptom endpoints and tolerability, the ADX-102 treatment was nominated for advancement.

The group said it now expects to initiate a phase 2b trial in the first half of 2018.

Aldeyra’s chief executive Todd Brady said: “These data represent the fourth set of positive phase 2 results with ADX-102 in ocular inflammation.

"The breadth of activity across noninfectious anterior uveitis, allergic conjunctivitis, and now dry eye disease confirms the potential of ADX-102 as an important and differentiated therapy in ophthalmology."

In reaction to the news, Aldeyra shares were up 52.38%, putting them on track to open at the highest level seen in over nine months.

View full ALDX profile View Profile

Aldeyra Therapeutics Timeline

Related Articles

Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
lab
March 15 2018
Amryt's lead drug candidate, AP101, is a potential treatment for epidermolysis bullosa, a rare genetic skin disorder for which there is currently no approved treatment
picture of cannabis plants
March 23 2018
Control of the supply chain offers operational advantages and financial benefits.
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use